fasudil has been researched along with Cytokine Release Syndrome in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xia, L | 1 |
| Yuan, LZ | 1 |
| Hu, YH | 1 |
| Liu, JY | 1 |
| Hu, GS | 1 |
| Qi, RY | 1 |
| Zhang, TY | 1 |
| Xiong, HL | 1 |
| Zheng, ZZ | 1 |
| Lin, HW | 1 |
| Zhang, JM | 1 |
| Yu, C | 1 |
| Zhou, M | 1 |
| Ma, J | 1 |
| Cheng, T | 1 |
| Chen, RR | 1 |
| Guan, Y | 1 |
| Xia, NS | 1 |
| Liu, W | 1 |
1 other study available for fasudil and Cytokine Release Syndrome
| Article | Year |
|---|---|
A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19.
Topics: Caspofungin; COVID-19; Cytokine Release Syndrome; Cytokines; Felodipine; Humans; Imatinib Mesylate; | 2023 |